Introduction {#s1}
============

The *PTEN* (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor gene is located on chromosome 10q23, a genomic region frequently lost in human cancers. Somatic deletions or mutations of this gene have been identified in a large fraction of tumors, frequently in prostate cancer (CaP), placing *PTEN* among the most commonly mutated tumor suppressor genes in human cancer ([@pbio.0000059-Cantley1]; [@pbio.0000059-Di1]).

As dictated by Knudson\'s "two-hit" hypothesis [@pbio.0000059-Knudson1], however, the analysis of cancer samples for mutations in *PTEN* has been performed searching for biallelic inactivation of the gene, which pointed at complete *PTEN* inactivation as a late event in cancer progression. The consequence of loss or mutation in one *PTEN* allele in carcinomas in situ or in primary cancers may have been underestimated. It could be postulated that if *PTEN* were to be haploinsufficient for some of its tumor-suppressive functions, loss of one *PTEN* allele or reduction in its expression may be playing a key role in tumor initiation, while further reduction of its function/expression may favor invasion and possibly tumor metastasis in advanced cancers.

In agreement with this hypothesis, it has been reported that primary tumors often show loss or alteration of at least one *PTEN* allele (e.g., 70%--80% of primary CaPs; [@pbio.0000059-Gray1]; [@pbio.0000059-Whang1]), while homozygous inactivation of *PTEN* is generally associated with advanced cancer and metastasis ([@pbio.0000059-Cantley1]; [@pbio.0000059-Di1]), supporting a possible key role for progressive *PTEN* functional loss in tumor progression.

The elucidation of the molecular basis for tumor initiation and progression in most epithelial neoplasms has been hindered by the lack of suitable laboratory and preclinical models that accurately reflect the genetic and histopathological progression of these cancers. Furthermore, the outcome of a progressive dose reduction in tumor suppressor function has been rarely assessed in vivo in the mouse. Small interfering RNA (siRNA) technology has more recently allowed testing the consequence of knockdown of a tumor suppressor such as p53 in specific cell types such as hemopoietic stem cells, by generating epi-allelic series of hypomorphs created by stable RNA interference (RNAi) transduction ([@pbio.0000059-Hemann1]). In the case of Pten, this analysis is further complicated since complete inactivation of the gene results in early embryonic lethality and aberrant developmental programs ([@pbio.0000059-Di2], [@pbio.0000059-Di4]; [@pbio.0000059-Suzuki1]; [@pbio.0000059-Podsypanina1]). Thus, a further unrestricted reduction of the Pten dose could still result in embryonic lethality. On the other hand, the consequence of complete *Pten* inactivation, even when restricted to a specific organ/tissue, could still affect the developmental program of that organ, while complete somatic loss of *Pten* in an adult organ would better approximate what is normally observed in human cancer. We have addressed these issues for *Pten*, as we describe in this article, through the generation of (i) hypomorphic mouse mutants and (ii) conditional mutants for complete prostate-specific *Pten* inactivation after puberty.

We previously reported that *Pten* heterozygous (*Pten*^+/−^) mutants are prone to develop neoplasms of various histological origins, including prostatic intraepithelial neoplasias (PIN) after a long latency ( \>14 mo) and at incomplete penetrance (40%) ([@pbio.0000059-Di4]). *Pten*^+/−^ mutants, however, never develop invasive CaPs. Invasive CaPs were, by contrast, observed in compound *Pten*^+/−^/*p27^Kip1^*^+/−^ or *Pten*^+/−^/*p27^Kip1^*^−/−^ mutants**(**[@pbio.0000059-Di4]). These lesions appeared to originate in PIN lesions, which then become invasive. However, no metastatic CaP was observed in this model, also in view of early lethality due to the occurrence of concomitant tumors of various histogenesis. Analysis of tumors, PIN, and CaP in *Pten*^+/−^ mice and *Pten*/*p27^Kip1^* compound mutants strongly suggested that *Pten* may be haploinsufficient in prostate tumor suppression since Pten protein expression was never lost in these lesions. If this was indeed the case, a further reduction in the Pten dose with respect to *Pten*^+/−^ mutants should impact on tumorigenesis and tumor progression. By contrast, in case Pten needed to be completely lost for phenotypic consequences to be manifest, only a complete *Pten* inactivation would hasten the neoplastic process.

The discovery that phosphatidylinositol 3,4,5-trisphosphate (PIP3) is the main in vivo substrate of PTEN ([@pbio.0000059-Maehama1]) placed this phosphatase into a well-defined pathway (reviewed in [@pbio.0000059-Vivanco1]). PIP3 levels are very low in quiescent cells, but rapidly increase upon stimulation by growth factors, through phosphoinositide 3-kinase (PI3K) activation. The role of PTEN is to keep the levels of PIP3 low by dephosphorylation at the D3 position. Loss of PTEN function results in increased PIP3 levels and subsequent Akt hyperactivation/phosphorylation ([@pbio.0000059-Stambolic1]; [@pbio.0000059-Di3]; [@pbio.0000059-Backman1]; [@pbio.0000059-Vivanco1]). It may therefore be proposed that a progressive reduction in the Pten dose could simply result in a concomitant progressive dose-dependent increase in Akt activation and its downstream molecular biological consequences. Alternatively, *Pten* expression levels may constitute discrete biochemical thresholds below which qualitative functional changes would occur, contributing to tumor progression and invasion.

CaP is the most common non-skin malignancy among Western adult males. It is estimated that in 2003, approximately 220,900 new cases and 28,900 CaP-related deaths will occur in the United States. Approximately 70% of CaP patients will harbor mutation or display loss of at least one allele of *PTEN* ensuing in the constitutive activation of the PI3K/mTOR pathway ([@pbio.0000059-Gray1]; [@pbio.0000059-Whang1]; [@pbio.0000059-Di1]). As aforementioned, those mutations are in positive correlation with tumor stage and grade, *PTEN* being completely lost in approximately 40% of metastatic CaPs ([@pbio.0000059-Gray1]; [@pbio.0000059-Whang1]). We therefore decided to focus on the prostate as an important model system to determine genetically whether and how the dose of Pten dictates tumor initiation and progression.

We demonstrate in vivo, in a hypomorphic mouse mutant series, that Pten plays a crucial dose-dependent role in CaP tumor suppression and that *Pten* progressive inactivation leads to both quantitative and qualitative molecular and biological changes towards full-blown tumorigenesis.

Results {#s2}
=======

Generation of a Hypomorphic *Pten* Mutant Series {#s2a}
------------------------------------------------

We have previously reported that *Pten* heterozygous mutants are tumor prone and viable, while complete *Pten* inactivation results in embryonic lethality ([@pbio.0000059-Di2], [@pbio.0000059-Di4]). We therefore decided to generate and characterize a mouse mutant in which the dose of Pten would be reduced further below the levels observed in a *Pten*^+/−^ mutant. To this end, we at first engineered by homologous recombination an allele of *Pten* that would express a wild-type *Pten* gene at reduced levels, taking advantage of the well-known phenomenon of transcriptional interference ([@pbio.0000059-McDevitt1]; [@pbio.0000059-Morita1]). We therefore targeted within *Pten* intron 3 the neomycin (Neo) cassette under the control of the strong CMV promoter ([Figure 1](#pbio.0000059-g001){ref-type="fig"}A; see also [Figure 3](#pbio.0000059-g003){ref-type="fig"}A) in mouse embryonic stem (ES) cells. Transcription of the Neo cassette in the recombined allele was expected to interfere with the transcription of the *Pten* gene, in turn resulting in lower expression levels of a wild-type Pten protein by this allele. Correctly recombined ES clones were obtained (see [Figure 3](#pbio.0000059-g003){ref-type="fig"}B; [see Materials and Methods](#s4){ref-type="sec"}) and injected into blastocysts for germline transmission. Mutants harboring the *Pten*^hy^ allele were obtained from recombined ES cells and were found viable, thriving, and fertile. We next intercrossed *Pten*^hy/+^ mice with *Pten*^+/−^ mice to generate a hypomorphic series ([Figure 1](#pbio.0000059-g001){ref-type="fig"}B).

![Production and Analysis of a *Pten* Hypomorphic Mouse Series\
(A) Schematic representation of the wild-type (*+*), hypomorphic (*hy*), and null (−) alleles of *Pten*. (For a detailed view, see [Figure 3](#pbio.0000059-g003){ref-type="fig"}A.)\
(B) Breeding scheme used to produce a *Pten* hypomorphic mouse series and predicted hierarchy of *Pten* expression levels.\
(C) WB analysis of MEF lysates from ten littermate primary cell cultures obtained from a single cross (indicated in \[B\]) confirms predicted *Pten* expression hierarchy in the hypomorphic series and inversely related Akt phosphorylation status (top), both verified by densitometric analysis and plotting of the Pten/actin and phospho-Akt/Akt ratios (bottom).\
(D) MEF cDNA was amplified by semiquantitative PCR with exon 3 (forward) and exon 4--5 spanning (reverse) primers for *Pten*. Consistent with the concept of transcriptional interference at the *Pten* locus, *Pten* mRNA levels in *Pten*^hy/−^ MEFs are clearly below the level observed in heterozygosity. Lower panels show the quantification of *Pten* relative to *Hprt* amplification.](pbio.0000059.g001){#pbio.0000059-g001}

![Conditional Knockout of the *Pten* Gene in Mouse Prostate\
(A) Map of wild-type *Pten* locus (top), targeting construct (second from top), predicted targeted locus (third from top), *Pten* locus after Cre-mediated excision of the Neo resistance cassette by crossing with an *EIIA-Cre* mouse (fourth from top), and *Pten* locus after Cre-mediated excision of the floxed exons 4 and 5 by crossing with a *PB-Cre* or *PB-Cre4* transgenic mouse (bottom). The genomic sequence is depicted as a black line, with black boxes representing exons 4 and 5. Pink and yellow boxes represent the Neo resistance and the HSV thymidine kinase cassette (TK) and light blue triangles represent the *loxP* site, respectively. The *Pten* genomic fragments used as a probe for Southern blot analysis are shown (3′ probe and probe 6.1). Solid arrows represent expected fragments following hybridization with the 3′ probe upon digestion with *Eco*RI, and dashed arrows represent expected fragments following hybridization with the probe 6.1 upon digestion with *Xba*I. Locations of PCR primers to detect wild-type, floxed allele (*Pten*^loxP^), and deleted allele are shown. *Xba*I (X), *Kpn*I (K), *Bam*HI (B), and *Eco*RI (E) sites are shown.\
(B) Genotyping of mice. Lanes 1 and 2 show Southern blot analysis of ES cell clones with 3′ probe of control (lanes 2) and recombined clones and \#176 (lane 1) after digestion with *Eco*RI, showing a 6 kb wild-type band (WT) and a 2.5 kb targeted band (R). Lanes 3 and 4 (control) represent Southern blot analysis of mouse tail DNA of offspring by crossing F1 mouse generated from \#176 with an *EIIA-Cre* mouse with probe 6.1 after digestion with *Xba*I, showing wild-type, targeted (*Pten*^loxP-neo^), and floxed (*Pten*^loxP^) locus bands. Lanes 5, 6 (control), and 7 represent Southern blot analysis of mouse tail DNA of offspring by crossing the mouse of lane 3 with a wild-type mouse with probe 6.1 after digestion with *Xba*I. Lanes 8--14 show PCR analysis of tail DNA of offspring by crossing a *PB-Cre4* (+), *Pten*^loxP/+^ male with a *Pten*^loxP/+^ female with primers 1 and 2. Lanes 8, 9, and 14 indicate *Pten*^loxP/+^ , lanes 10 and 13 indicate *Pten*^+/+^,and lanes 11 and 12 indicate *Pten*^loxP/loxP^. Lanes 15--17 show PCR analysis of tail DNA of offspring by crossing a *Pten*^loxp/+^ male with a *PB-Cre4*(+), *Pten*^loxP/+^ female with primers 1, 2, and 3. Lane 15 indicates *Pten*^loxP/+^, lane 16 indicates *Pten*^+/+^, and lane 17 indicates that the deleted allele exists in tail DNA of this offspring.\
(C) Representation of crossing scheme used to generate prostate-specific *Pten* conditional mutants. *Pten*^loxP/loxP^ mutants were crossed with *PB-Cre* transgenic mice or *PB-Cre4* transgenic mice.](pbio.0000059.g003){#pbio.0000059-g003}

Partial Rescue of Embryonic Lethality in *Pten* Hypomorphic Mutants {#s2b}
-------------------------------------------------------------------

The further reduction of the Pten dose could indeed result in embryonic lethality; we therefore assessed whether compound *Pten*^hy/−^ mice would be born at all. In the analyzed cohort (*n* = 190), viable male and female *Pten*^hy/−^ mutants were in fact obtained. However, the frequencies among various genotypes did not follow Mendelian ratios. Out of the 25% *Pten*^hy/−^ mutants expected in these crosses, only 10% were born. In particular, approximately 40% of the *Pten*^hy/−^ males and 75% of the *Pten*^hy/−^ females were lost during gestation. This strongly suggested that a further reduction of the Pten dose had occurred in *Pten*^hy/−^ mutants and that this reduction still results in embryonic lethality, albeit at incomplete penetrance (the embryonic phenotype of the *Pten*^hy/−^ will be described elsewhere; L. C. Trotman and P. P. Pandolfi, unpublished data). Enough viable *Pten*^hy/−^ males were obtained, however, and monitored for tumorigenesis in the prostate. As predicted, a significant reduction in Pten levels and the consequent increase in Akt activation (phospho-Akt/Akt ratio) were observed in organs and primary cells from *Pten*^hy/−^ mutants when compared to *Pten*^+/−^, *Pten*^hy/+^, and wild-type littermates. In particular, we analyzed mouse embryonic fibroblasts (MEFs), peripheral blood mononuclear cells (PBMCs), and prostates of various genotypes ([Figure 1](#pbio.0000059-g001){ref-type="fig"}C; [Figure 2](#pbio.0000059-g002){ref-type="fig"}A and [2](#pbio.0000059-g002){ref-type="fig"}B; data not shown). Semiquantitative RT--PCR analysis confirmed the reduction of *Pten* mRNA expression in *Pten*^hy/−^ MEFs when compared to *Pten*^+/−^ and wild-type cells (see [Figure 1](#pbio.0000059-g001){ref-type="fig"}D).

![*Pten*^hy/−^ Mice Display Massive Hyperplasia and Invasive CaP\
(A) IHC on preneoplastic anterior prostate (AP) tissue of 2-mo-old littermate mice shows decreasing Pten protein levels in the hypomorphic series.\
(B) WB analysis of the prostate lobes from (A) is shown on the left and their quantification is shown on the right.\
(C) MRI of *Pten*^hy/−^ mice aged 6--8 mo shows pathologic structures (encircled by dashed lines) adjacent to seminal vesicles (SV) coinciding with displacement of the bladder (Bl), features typically associated with massive prostate tumors (right). These features were never found in *Pten*^+/+^ or *Pten*^+/−^ mice (left).\
(D) Macroscopic view of the *Pten*^hy/−^ mouse from (C) confirms massive enlargement of the AP lobes, but normal-sized seminal vesicles.\
(E) Quantification of WB analysis on AP lobe total lysates from the *Pten*^hy/−^ animal shown in (C) compared to preneoplastic AP of same genotype from (A) and (B), labeled 8 mo and 2 mo, respectively. Note that in the enlarged hyperplastic prostate, Pten protein expression is retained (levels are expressed relative to the corresponding wild-type animals).\
(F) Histopathology (H&E) of AP lesions at 8 mo reveals transition from low- to high-grade PIN and invasion (infiltration of stromal tissue is indicated by arrows) in *Pten*^hy/−^, while age-matched *Pten*^+/−^ tissue only shows hyperplastic features and *Pten*^+/+^ tissue is unaffected. Bars are 50 μm.](pbio.0000059.g002){#pbio.0000059-g002}

Massive Prostate Hyperplasia and Invasive CaP in *Pten*^hy/−^ Mutants {#s2c}
---------------------------------------------------------------------

The levels of Pten were indeed further reduced in the prostates from *Pten*^hy/−^ mutants when compared to wild-type, *Pten*^hy/+^, and *Pten*^+/−^ mice ([Figure 2](#pbio.0000059-g002){ref-type="fig"}A and [2](#pbio.0000059-g002){ref-type="fig"}B). Conversely, Akt activation was increased in *Pten*^hy/−^ mutants ([Figure 2](#pbio.0000059-g002){ref-type="fig"}B). On this premise, we therefore studied prostate tumorigenesis in *Pten*^hy/+^ (*n* = 26), *Pten*^+/−^ (*n* = 24 in this study plus *n* = 18, as previously reported; [@pbio.0000059-Di4]), and *Pten*^hy/−^ (*n* = 14) mutants on a comparative basis. Mice were followed throughout their lives according to the following experimental scheme: (i) all cohorts were subjected to serial monthly (in selected cases, biweekly) nuclear magnetic resonance imaging (MRI) ([see Materials and Methods](#s4){ref-type="sec"}) for detection of morphological changes in the size and shape of the prostate; (ii) mice were sacrificed at or prior to tumor detection for postmortem pathological analysis or when manifest sign of distress were observed (owing to tumor codevelopment; *Pten*^hy/−^ mutants, as *Pten*^+/−^ mice, in fact, developed tumors of multiple histologic origins; data not shown). Striking differences were observed in the prostates of these three cohorts over time. The prostates of *Pten*^+/+^ and *Pten*^+/−^ mice were never found enlarged by MRI analysis at any age ([Figure 2](#pbio.0000059-g002){ref-type="fig"}C; see [Figure 5](#pbio.0000059-g005){ref-type="fig"}D). *Pten*^+/−^ mutants developed moderate/low-grade PINs at incomplete penetrance (35%--40% approximately, after a long latency of \>12 mo) that were only detected by serial postmortem analysis, as previously reported ([Figure 2](#pbio.0000059-g002){ref-type="fig"}F; [@pbio.0000059-Di4]). Strikingly, however, MRI analysis immediately revealed a profound difference in the *Pten*^hy/−^ cohort. The prostates of these mice were found markedly enlarged, and prostate growths were detected starting at 3 mo (see [Figure 5](#pbio.0000059-g005){ref-type="fig"}D). By 6--8 mo, these growths typically surpassed the size of seminal vesicles ([Figure 2](#pbio.0000059-g002){ref-type="fig"}C and [2](#pbio.0000059-g002){ref-type="fig"}D). Interestingly, prostate enlargements were not accompanied by an overall increase in total body weight or size in *Pten*^hy/−^ mutants (data not shown). Postmortem pathological analysis of such mutants confirmed the marked epithelial hyperplasia of the prostate ([Figure 2](#pbio.0000059-g002){ref-type="fig"}F). All lobes were found to be hypercellular, with prominent macroscopic enlargements of anterior and dorsolateral lobes. Microscopically, the regular and round prostatic glands observed in wild-type mice were replaced by large, irregular, and complex glands that contained multiple intraluminal papillary projections already at age 2--3 mo. Furthermore, many cells had sizeable nuclei, clumped chromatin, and prominent nucleoli, forming foci of epithelial dysplasia.The phenotype observed in the *Pten*^hy/−^ mice was characterized by a wide spectrum of levels of cellular differentiation, which was not typically observed in the *Pten*^+/−^ mice. As we previously reported in *Pten*^+/−^ and *Pten*^+/−^/*p27^Kip1^*^−/−^ mutants ([@pbio.0000059-Di4]), Pten protein expression was also still retained in the hyperplastic prostates from *Pten*^hy/−^ mutants, and Southern blot analysis confirmed retention of the hypomorphic *Pten* allele ([Figure 2](#pbio.0000059-g002){ref-type="fig"}E; data not shown). Importantly, approximately 25% of the *Pten*^hy/−^ mice analyzed at more than 6 mo of age showed histological signs of local invasion, with tumor cells disrupting the basement membrane of the gland and growing into the surrounding stroma ([Figure 2](#pbio.0000059-g002){ref-type="fig"}F; see [Figure 5](#pbio.0000059-g005){ref-type="fig"}E). Thus, strikingly, a further reduction in the Pten dose as observed in *Pten*^hy/−^ mutants when compared with *Pten*^+/−^ mutants does lead to massive prostate hyperplasia at complete penetrance and accelerates tumor progression from high-grade PIN (grade 3--4 tumor as per the CaP grading system for genetically engineered mice; [@pbio.0000059-Park1]) to locally invasive CaP in this mouse model.

![Molecular Effects of Loss of *Pten* and Biological Comparison of All Generated Mouse Models\
(A) Ki-67 staining of AP lobe sections illustrates increasing proliferation with decreasing Pten levels (numbers are Ki-67-positive cells per 300 cells counted in percent; bars are 50 μm).\
(B) The phospho-Akt/Akt ratio is sharply increased in the prostates of 10-wk-old *Pten*^pc2^ animals, as shown by densitometric quantification of WB analysis.\
(C) AP staining with anti-phospho-Akt antibodies reveals strong plasma membrane localization of phospho-Akt and apparent reduction of p27 protein detection, whereas phospho-mTOR and phospho-threonine-FOXO3 antibodies show increased staining in *Pten*^pc2^ versus wild-type mouse prostates. Bars are 50 μm.\
(D) Kaplan--Meier curve showing prostate enlargement as visualized by MRI. Progressive rates of mass increase for *Pten*^pc2^ (median age, 4 mo), *Pten*^hy/−^ (median age, 7 mo), and *Pten*^pc1^ (median age, 16 mo) mice are found. In contrast, no prostatic size irregularities were detected in *Pten^+/+^* or *Pten^+/−^* mice.\
(E) Incidence of invasive CaP. Invasive CaP was defined as tumor cells disrupting the basal membrane of prostatic glands and growing into the surrounding stroma. Full penetrance was observed in both *Pten^pc1^* mice as well as in *Pten^pc2^* mice. In contrast, *Pten^hy/−^* mice with a follow-up of more than 6 mo displayed only 25% incidence of invasive CaP.](pbio.0000059.g005){#pbio.0000059-g005}

Generation of Conditional Prostate-Specific *Pten* Mutants {#s2d}
----------------------------------------------------------

We next determined whether complete *Pten* inactivation in the prostate would further affect CaP tumor progression. To this end, we generated mouse mutants in which *Pten* exons 4 and 5 are flanked by *loxP* sites ([Figure 3](#pbio.0000059-g003){ref-type="fig"}A; [see Materials and Methods](#s4){ref-type="sec"}). The Neo cassette was excised from the locus in vivo by intercrossing *Pten*^hy/+^ with *EIIA-Cre* transgenic mice ([@pbio.0000059-Lakso1]). In these mice, the *Cre* recombinase is expressed transiently, early in embryogenesis, allowing the production of a mosaic progeny that harbors in the germline *Pten* alleles in three different configurations: targeted unmodified (still retaining the Neo cassette), *Pten* floxed, or *Pten* deleted ([Figure 3](#pbio.0000059-g003){ref-type="fig"}A). Breeding of these mosaic mutants allowed us to generate mice heterozygous for the *Pten* floxed allele (*Pten*^loxP^ mutants; see [Figure 3](#pbio.0000059-g003){ref-type="fig"}B).

As expected, *Pten*^loxP^ mice were born following Mendelian frequencies, viable and fertile, and were utilized for the conditional inactivation of the *Pten* gene in the prostate. To this end, we made use of two different *Cre* transgenic lines, *PB-Cre* and *PB-Cre4*, in which the *Cre* gene is under the control of two distinct versions of the rat *Probasin* (*PB*) gene promoter ([@pbio.0000059-Maddison1]; [@pbio.0000059-Wu1]). The *PB* gene is expressed in the prostatic epithelium postpuberty since the gene is androgen responsive ([@pbio.0000059-Matusik1]). Hence, using both *PB-Cre* transgenic lines, excision of the *Pten* gene would occur in the prostatic epithelium postpuberty. This is of relevance because it avoids any possible developmental effect due to complete inactivation of *Pten* during prostate organogenesis. The main difference in the two lines essentially resides in the strength of the promoter. In the *PB-Cre4* line ([@pbio.0000059-Wu1]), the *Cre* gene is driven by a composite promoter, *ARR~2\ PB~*, which is a derivative of the rat *PB* promoter from which the *PB-Cre* line ([@pbio.0000059-Maddison1]) was originally generated. *PB-Cre4* mice express *Cre* at high levels and at high penetrance, while *PB-Cre* mice express *Cre* at lower levels and in fewer cells. This could in turn result in a more focal or more diffuse inactivation on *Pten* in the prostatic epithelium, as we could indeed document ([Figure 4](#pbio.0000059-g004){ref-type="fig"}A). Also of note, *PB-Cre* and *PB-Cre4* mice were crossed with *Pten*^loxP^ mutants in order to generate *PB-Cre/Pten*^loxP/loxP^ (hereafter referred to as *Pten*^pc1^ mutants) or *PB-Cre4/Pten*^loxP/loxP^ (hereafter referred to as *Pten*^pc2^ mutants) (see [Figure 3](#pbio.0000059-g003){ref-type="fig"}C).

![*Pten*^pc2^ Mice Develop Invasive CaP\
(A) Histopathology analysis of wild-type, *Pten*^pc1^, and *Pten*^pc2^ mice prior to tumor onset. H&E-stained AP (top) shows the difference in both the morphology and proliferative rates of the prostatic epithelium in these two models. IHC staining with anti-Pten antibody (bottom) was carried out on wild-type, *Pten*^pc1^, and *Pten*^pc2^ mice. In wild-type mice, strong cytoplasmic staining was observed in epithelial cells (arrowheads). In *Pten*^pc1^ mice, staining was generally weak, whereas in *Pten*^pc2^ mice, staining was completely absent in the prostatic epithelium. Original magnification, 400×.\
(B) MRI (top) shows massive prostate tumor (surrounded by dashed line) in *Pten*^pc2^ mice (at 6 mo) and no detectable difference between the prostates of *Pten*^pc1^ or *Pten*^+/+^ mice (at 12 mo; arrowheads). Bladder (Bl) and seminal vesicles (SV) are indicated. Macroscopic view (second from top) of the same animals confirms massive enlargement of both APs in *Pten*^pc2^ and reveals the slightly enlarged AP of *Pten*^pc1^ mice (encircled). H&E staining (bottom) of the prostate from *Pten*^pc1^ mice was characterized by multiple foci of PIN lesions and by the presence of prostatic adenocarcinoma. These lesions contained well-differentiated neoplastic cells and showed focal areas of invasion (arrowheads). H&E stainings of prostates from *Pten*^pc2^ mice showed diffuse, invasive CaP with large, undifferentiated tumor cells growing into stromal areas.](pbio.0000059.g004){#pbio.0000059-g004}

The Dose of Pten Dictates Tumor Progression in the Prostate {#s2e}
-----------------------------------------------------------

We next studied the impact of complete *Pten* inactivation on prostate tumorigenesis in *Pten*^pc1^ and *Pten*^pc2^ mutants. Mice were followed over time exactly as described for the *Pten* hypomorphic series by serial MRI and pathological analysis over a period of approximately 18 mo ([Figure 5](#pbio.0000059-g005){ref-type="fig"}D and [5](#pbio.0000059-g005){ref-type="fig"}E). Strikingly, we observed a dramatic difference in *Pten*^pc1/2^ mutants when compared to *Pten*^hy/−^ mutants, but also, importantly, when comparing *Pten*^pc1^ with *Pten*^pc2^ mutants. MRI and macroscopic postmortem analysis of the prostate revealed a rapid massive enlargement of all the prostatic lobes already manifested from 2--3 mo of age in *Pten*^pc2^ mutants at complete penetrance (see [Figure 4](#pbio.0000059-g004){ref-type="fig"}B; [Figure 5](#pbio.0000059-g005){ref-type="fig"}D). In *Pten*^pc1^ mutants, the enlargement was less pronounced at early stages and undetectable by MRI, but still apparent (see [Figure 4](#pbio.0000059-g004){ref-type="fig"}B; [Figure 5](#pbio.0000059-g005){ref-type="fig"}D). As aforementioned, the pattern of *Pten* inactivation in the prostatic epithelium was different in *Pten*^pc1^ versus *Pten*^pc2^ mutants (see [Figure 4](#pbio.0000059-g004){ref-type="fig"}A; *Pten*^pc1^ focal versus *Pten*^pc2^ widespread). This difference also correlated with a clear difference in both the morphology and proliferative rates of the prostatic epithelium in these two models (see [Figure 4](#pbio.0000059-g004){ref-type="fig"}A; see also the following paragraph). Thus, *Pten*^pc2^ mutants displayed a much more severe prostate enlargement than did *Pten*^pc1^ mutants (see [Figure 4](#pbio.0000059-g004){ref-type="fig"}B; [Figure 5](#pbio.0000059-g005){ref-type="fig"}D). *Pten*^pc1^ mice displayed focal areas of epithelial hyperplasia, with enlarged glands formed by relatively regular cells, while *Pten*^pc2^ mice presented disorganized hyperplastic glands in all lobes with signs of cellular dysplasia, containing large, irregular cells, forming at times cryptic glandular formations (see [Figure 4](#pbio.0000059-g004){ref-type="fig"}A).

Even more strikingly, however, pathological analysis of prostates from *Pten*^pc1^ and *Pten*^pc2^ mice revealed in both mutants, at complete penetrance, the development of invasive and diffuse CaP after a variable latency (see [Figure 4](#pbio.0000059-g004){ref-type="fig"}B; [Figure 5](#pbio.0000059-g005){ref-type="fig"}E). Tumors were in both cases made of *Pten* null cells (data not shown). Continuity of local invasive disease with that of intraepithelial lumens was often observed. The tumors were composed of rather large, mature epithelial cells. Neuroendocrine features, such as cytoplasmic granularity and small round cells, were not seen in the tumors analyzed (see [Figure 4](#pbio.0000059-g004){ref-type="fig"}B). Although the tumors were clearly invasive in both *Pten*^pc1^ and *Pten*^pc2^ mutants with disruption of the basement membrane and clear signs of organ infiltration, once again we observed differences in the CaPs from these two models. In many instances, in *Pten*^pc2^ mutants more than one prostate lobe was completely effaced by the infiltrating neoplastic cells, suggesting a multifocal tumor origin, while invasive tumors in *Pten^pc1^* mutants were often affecting only one lobe at a time and the extent of the infiltration was less diffuse (see [Figure 4](#pbio.0000059-g004){ref-type="fig"}B). In addition, tumors in the *Pten*^pc1^ animals were well-to-moderately differentiated while tumors in the *Pten*^pc2^ mice were in general high-grade, undifferentiated lesions. In contrast, *Pten^hy/−^* mutants displayed a spectrum of phenotypes, from well to undifferentiated and occasionally to locally invasive phenotypes, as previously shown.

Thus, *Pten* conditional inactivation in the prostate leads to invasive and diffuse CaP at complete penetrance.

Effects of the Pten Dose on the Biology of the Prostatic Epithelium {#s2f}
-------------------------------------------------------------------

We studied the molecular and biological consequences of Pten dose variations in the prostatic epithelium of our various mutants. We included in the analysis age-matched (8-wk-old) *Pten*^+/+^, *Pten*^+/−^, *Pten*^hy/−^, and *Pten*^pc2^ males. The latter mutants were used instead of *Pten*^pc1^ mice in view of the more widespread pattern of *Pten* inactivation observed in their prostates.

First, we determined whether reduction in the Pten dose would affect proliferation of epithelial cells. Upon Ki-67 staining, we observed a progressive increase in the proliferative rates of prostate epithelial cells, which correlated with the reduction in *Pten* expression levels ([Figure 5](#pbio.0000059-g005){ref-type="fig"}A). For instance, approximately 10-fold more cells were found in active proliferation in the prostates from *Pten*^pc2^ mutants when compared with *Pten*^+/+^ mice. Thus, *Pten* inactivation, in a dose-dependent manner, lends to epithelial cells a dramatic growth advantage in the prostate. By contrast, MEFs of all genotypes from the hypomorphic series did not show noticeable differences in their growth rates under standard culture conditions, while showing progressive activation of the Akt signaling pathway (data not shown; see [Figure 1](#pbio.0000059-g001){ref-type="fig"}C). This may reflect an intrinsic differential cell-type sensitivity to *Pten* inactivation, also in agreement with the fact that *Pten* hypomorphism does not result in overall increased body size and weight.

We next assessed whether and how the progressive reduction of the Pten dose would affect the functions of key downstream targets such as Akt, p27^Kip1^, mTOR, and FOXO3 by immunohistochemistry (IHC) and Western blot (WB) analysis ([see Materials and Methods](#s4){ref-type="sec"}). As aforementioned, we studied the status of Akt phosphorylation, the major known biochemical effect of Pten loss ([@pbio.0000059-Vivanco1]), using an anti-phospho-Akt-specific antibody on cells and extracts from the various *Pten* mutants. Staining of prostates from various genotypes with this antibody increased proportionally to the decrease in Pten levels as confirmed by WB analysis (see Figures [2](#pbio.0000059-g002){ref-type="fig"}B, [5](#pbio.0000059-g005){ref-type="fig"}B, and [5](#pbio.0000059-g005){ref-type="fig"}C; data not shown). In addition, IHC analysis revealed a drastically different staining pattern in prostate cells from *Pten*^pc2^ mutants when compared with cells from other genotypes in that phospho-Akt was found to overtly accumulate at the plasma membrane ([Figure 5](#pbio.0000059-g005){ref-type="fig"}C). A similar staining pattern was observed both in *Pten* null epithelium prior to tumor occurrence and in cells from overt tumors from both *Pten*^pc1^ and *Pten*^pc2^ mutants (data not shown). Thus, Akt is progressively activated by a reduction in the Pten dose, which in turn results in its recruitment to the plasma membrane.

We next studied the effects of *Pten* inactivation on p27^Kip1^, FOXO3, and mTOR, known targets of Akt kinase activity. Phosphorylation of p27^Kip1^ and FOXO3 by Akt results in their functional inactivation through multiple mechanisms such as nuclear export, in the case of FOXO ([@pbio.0000059-Brunet1]), or inhibition of nuclear import and downregulation, in the case of p27^Kip1^ ([@pbio.0000059-Mamillapalli1]; [@pbio.0000059-Liang1]; [@pbio.0000059-Shin1]; [@pbio.0000059-Viglietto1]). By contrast, Akt activation results in mTOR phosphorylation and increased protein translation and translation initiation ([@pbio.0000059-Gingras1]). We previously reported that the localization or the expression levels of p27^Kip1^ were not affected in *Pten*^+/−^ and *Pten*^+/−^/*p27^Kip1^*^−/−^ compound mutants ([@pbio.0000059-Di4]). By contrast, a progressive downregulation in p27^Kip1^ staining was observed in *Pten*^hy/−^ and *Pten*^pc2^ mutants ([Figure 5](#pbio.0000059-g005){ref-type="fig"}C; data not shown). p27^Kip1^ was apparently expressed at lower levels, and fewer cells were found to express the protein ([Figure 5](#pbio.0000059-g005){ref-type="fig"}C). We also studied the status of FOXO3 in the various *Pten* mutants, analyzing both its localization and threonine phosphorylation with a specific anti-phospho-FOXO3 antibody ([see Materials and Methods](#s4){ref-type="sec"}). While no noticeable differences were observed in *Pten*^+/−^ and *Pten*^hy/−^ mutants (data not shown), increase in the levels of anti-phospho-FOXO3 cytoplasmic staining were observed in prostate epithelial cells from *Pten*^pc2^ mutants when compared to wild-type mice ([Figure 5](#pbio.0000059-g005){ref-type="fig"}C). Complete *Pten* inactivation also resulted in an increase in mTOR phosphorylation in the prostatic epithelium of *Pten*^pc2^ mutants ([Figure 5](#pbio.0000059-g005){ref-type="fig"}C).

Thus, the progressive reduction of the Pten dose (and the extent of *Pten* inactivation in *Pten*^pc1/2^ mutants) affects the proliferative rate of the prostatic epithelium and results in molecular changes, which in turn dictates the natural history of these lesions and tumor progression ([Figure 5](#pbio.0000059-g005){ref-type="fig"}D and [5](#pbio.0000059-g005){ref-type="fig"}E).

Discussion {#s3}
==========

Our analysis allows a detailed deconstruction the molecular genetics underlying cancer progression in the prostate and the assessment of the key relevance of Pten and subtle variations in its dose in controlling this process. Based on our findings, we can now attribute distinct preneoplastic or malignant pathological entities to distinct molecular states. Furthermore, this new knowledge allows the reclassification, on the basis of their true molecular nature, of pathological lesions that at a superficial analysis appeared very similar ([Figure 6](#pbio.0000059-g006){ref-type="fig"}).

![Pten Dose Affects Prostate Tumor Progression\
*Pten*^+/−^ mice develop hyperplasia, dysplasia, and low-grade PIN. *Pten*^hy/−^ mice develop at complete penetrance high-grade PIN at a young age (8--10 wk) and roughly 25% present invasive CaP around 8 mo. *Pten*^pc^ mice develop invasive CaP at complete penetrance. (See Discussion for a detailed description.) *p27^Kip1−/−^* mice, on the contrary, develop only BPH. Possibilities for human therapeutic intervention derived from our findings: in addition to inactivation of PI3K/AKT and mTOR enzymatic activities (in *PTEN* loss of heterozygosity condition), monitoring and elevation of PTEN expression levels of the remaining allele could not only prevent formation of PIN lesions (in *PTEN*^+/−^ individuals), but could importantly also be used to counteract the progression to invasive phenotypes (as observed in *Pten*^hy/−^mouse mutants).](pbio.0000059.g006){#pbio.0000059-g006}

In this supposedly linear and multistep process, which separates two extremely different anatomical and pathological entities, a normal prostatic epithelium from an invasive CaP, there are, in between, a discrete number of anatomically distinct intermediary steps, such as prostate hyperplasia \> displasia/low-grade PIN \> high-grade PIN \> locally invasive CaP \> diffused CaP. These entities have been recognized before on the basis of their pathological features. The fact that we are now able to correlate these anatomical stages with specific molecular events, such as the level of expression of a single tumor suppressor gene, not only represents an integration of anatomical, descriptive findings with biological data, but also offers the opportunity of therapeutic interventions.

We show in this study that inactivation of one *Pten* allele in the mouse may lead to prostate epithelial hyperplasia, as complete inactivation of p27^Kip1^ in the mouse leads to what resembles human benign prostate hyperplasia (BPH). However, these two lesions are very different in nature and outcome: the first, in fact, impacts only on epithelial elements and over time evolves to low-grade PIN, while the second impacts on both epithelial and stroma elements, representing hyperplasia of the whole organ, but does not evolve toward malignancy ([Figure 6](#pbio.0000059-g006){ref-type="fig"}; [@pbio.0000059-Cordon-Cardo1]; [@pbio.0000059-Di4]). This obviously does not exclude that loss of p27^Kip1^ expression when accompanied by additional genetic events (e.g., loss of PTEN) may lead to a completely different outcome, as is also supported by our previous in vivo analysis in the mouse ([Figure 6](#pbio.0000059-g006){ref-type="fig"}; [@pbio.0000059-Di4]).

Moreover, our data demonstrate that a further reduction in the Pten dose, as observed in the *Pten*^hy/−^ mutants, accelerates tumor progression dramatically, eventually resulting in high-grade PIN and locally invasive carcinoma ([Figure 6](#pbio.0000059-g006){ref-type="fig"}). This fact has very important therapeutic implications. As a large number of CaP patients (more than 80%) display at presentation loss of one *PTEN* allele, but do retain the other normal *PTEN* allele, it could be proposed that high-grade PIN or locally invasive prostate carcinomas could be prevented or treated by pharmacologically modulating the expression of the remaining *PTEN* allele or by antagonizing the downstream consequences of *PTEN* downregulation or partial inactivation (e.g., PI3K/mTOR activation; [Figure 6](#pbio.0000059-g006){ref-type="fig"}).

While the massive prostate hyperplasia/dysplasia observed in the *Pten*^hy/−^ mutants is not, as expected, accompanied by complete loss of *Pten* expression (see [Figure 2](#pbio.0000059-g002){ref-type="fig"}E), the low penetrance of the invasive CaP in these mutants strongly suggest that additional events have to occur for this pathological transition to occur. Nevertheless, it is important to underscore that *Pten*^+/−^ mice, unlike *Pten*^hy/−^ mutants, do not develop invasive CaP, but only low-grade PIN lesions ([Figure 6](#pbio.0000059-g006){ref-type="fig"}). Thus, a further reduction of the Pten dose seems to be essential for this process. Several possibilities, not mutually exclusive, could be entertained: (i) a more severe reduction in the Pten dose could facilitate cooperative tumorigenesis by rendering the cells permissive and sensitive to the activation of additional oncogenic pathways; (ii) the massive prostate hyperplasia could facilitate the accumulation of additional genetic hits (including complete *Pten* loss) by simply expanding the pool of actively dividing cells; (iii) a more severe reduction in the Pten dose could protect cells from apoptotic programs that are normally triggered by the occurrence of damaging genetics events.

The fact that *Pten*^hy/−^ mutants develop massive prostate hyperplasia not accompanied by an overall increase in body weight and size underscores the fact that different tissues and organs are differentially sensitive to Pten dose variations, the prostatic epithelium being one of the most sensitive. In agreement with this notion, MEFs from *Pten*^hy/−^ mutants do not display proliferative advantage in standard culture condition over wild-type MEFs. In this respect, it is also important to remember that, unlike *p27^Kip1^*^−/−^ mice, which display hyperplasia of both stromal and parenchymal components in the prostate (as well as an increase in body mass; [@pbio.0000059-Fero1]; [@pbio.0000059-Kiyokawa1]; [@pbio.0000059-Nakayama1]), in *Pten*^hy/−^ mutants it is specifically the prostatic epithelium that actively proliferates, leading to prostate hyperplasia ([Figure 6](#pbio.0000059-g006){ref-type="fig"}). Interestingly, this does not parallel what is observed in other model systems, such as *Drosophila*, where dose variations in the expression of *Pten* or downstream signaling components (e.g., TOR) do result in variations in body size and mass (reviewed in [@pbio.0000059-Oldham1]).

While we and others had previously implicated *Pten* heterozygous loss in prostate tumorigenesis when in cooperation with additional oncogenic events (such as loss of p27^Kip1^ or *Nkx3.1* or the expression of the large T oncogene; [@pbio.0000059-Di4]; [@pbio.0000059-Kwabi-Addo1]; [@pbio.0000059-Kim1]; [@pbio.0000059-Abate-Shen1]), we demonstrate in this article that complete inactivation of *Pten* alone in the prostate has already catastrophic consequences leading to invasive, diffuse, and highly aggressive malignancies ([Figure 6](#pbio.0000059-g006){ref-type="fig"}). Although it cannot be formally excluded that complete *Pten* loss would still cooperate with additional oncogenic events toward full-blown transformation, this finding underscores once more the exquisite sensitivity of the prostatic epithelium to loss of *Pten*. This information should be factored in when tailoring the treatment of CaP or high-grade PIN lesions that have completely lost *PTEN* function. These lesions may be extremely sensitive to PI3K or mTOR inhibitors, while modulation of *PTEN* expression would not be a therapeutic option in these cases ([Figure 6](#pbio.0000059-g006){ref-type="fig"}). On the basis of these findings, it would seem therefore of paramount importance to routinely assess the status of the *PTEN* gene and its expression in human CaPs and precancerous lesions as a key biomarker to opt for the most appropriate therapeutic or chemopreventive intervention modalities. It remains to be seen whether complete *Pten* inactivation in the mouse prostate also influences the metastatic potential of these invasive CaPs alone or in combination with additional oncogenic events. In this respect, while MRI and postmortem analyses have indeed revealed the presence of lung neoplastic lesions in our conditional *Pten* mutants, morphological and molecular analyses have so far excluded the metastatic nature of these tumors (M. Niki et al., unpublished data).

The stepwise reduction in the Pten dose results in clear *progressively quantitative* changes in the prostate epithelial cells prior to tumor development. Increased cellular proliferation correlates with increased phosphorylation of Akt. In *Pten* null epithelial cells, both in the preneoplastic stage or in overt CaPs, phospho-Akt is found to accumulate almost exclusively at the plasma membrane (see [Figure 5](#pbio.0000059-g005){ref-type="fig"}C). Whether this represents the extreme consequence of Akt superactivation or rather reflects a genuine qualitative change in Akt biology and function in *Pten* null prostate epithelial cells remains to be determined. It also remains to be resolved whether the reduction in p27^Kip1^ expression is also associated with its cytoplasmic relocalization, as previously reported in human breast cancer cells suffering AKT hyperactivation ([@pbio.0000059-Liang1]; [@pbio.0000059-Shin1]; [@pbio.0000059-Viglietto1]). Taken together, this analysis supports a Pten dose-dependent model with *progressive* changes at the molecular level, arguing against a Pten threshold model for tumor suppression.

By contrast, clear *qualitative* morphological changes were observed in the prostate epithelium when analyzing the *Pten* hypomorphic series. While *Pten*^+/−^ mice never display massive prostatic enlargement, further reduction to *Pten*^hy/−^ levels leads to a sharp increase in prostate mass. In addition, *Pten*^+/−^ mice never develop invasive CaP, whereas *Pten*^hy/−^ mice do ([Figure 6](#pbio.0000059-g006){ref-type="fig"}). These data clearly support a threshold model for Pten tumor suppression at the physiopathological level.

Similarly, qualitative morphological changes are also caused by the number of cells suffering complete *Pten* inactivation, as observed when comparing *Pten*^pc1^ versus *Pten*^pc2^ mice. In *Pten*^pc2^ mice, signs of cellular dysplasia and irregular glandular formations were frequently observed, but they were mostly absent from *Pten*^pc1^ mutants. Along the same tenet, profound mass increase was always observed at early timepoints in *Pten*^pc2^ mice, but not in *Pten*^pc1^ mutants. This is likely due to the marked difference in the number of *Pten* null cells present in the parenchyma of these two models at puberty, reflecting the different levels of *Cre*expression in the two models. These observations are also consistent with a threshold model for *Pten* tumor suppression as a function of the number of *Pten* null cells in a given organ.

From a biological standpoint, it will be challenging to determine in the future whether this "field effect" would also play a role in the natural history of human CaP. On the one hand, it could be speculated that human CaP likely arises from a single transformed cell and that therefore that the field effects observed in mouse models will not be critical determinants in the natural history of the human disease. On the other hand, the multistep nature of the neoplastic process (and hence the genetic heterogeneity of the lesion) and the fact that the tumor will eventually grow to form "fields" of neoplastic cells may suggest that these effects, as well as stromal and parenchymal interactions, are key aspects of the human disease that the mouse model can recapitulate.

Taken together, our findings demonstrate the key importance of Pten in CaP tumor suppression and the dramatic impact that subtle changes in Pten levels and extent of *Pten* inactivation may have on tumor initiation and progression in the prostate.

Materials and Methods {#s4}
=====================

 {#s4a}

### Mice {#s4a1}

Generation and characterization of *Pten*^+/−^ mice have been described perviously ([@pbio.0000059-Di2], [@pbio.0000059-Di4]). Mice were genotyped by PCR on tail DNA or by Southern blotting as shown. Hypomorphic mice were generated as described in [Figure 1](#pbio.0000059-g001){ref-type="fig"} and [Figure 3](#pbio.0000059-g003){ref-type="fig"} and tail DNA genotyped by PCR for presence of the *Pten***^−^** and *Pten*^hy^ alleles (using primers 1 and 2 described below) or by Southern blotting.

### Targeting vector and generation of prostate-specific *Pten*-deficient mice {#s4a2}

A 129/Sv mouse genomic library (Stratagene, La Jolla, California, United States) was screened with a mouse *Pten* probe containing exons 4--6. To generate the targeting construct, a 4.1 Kb *Kpn*I--*Bam*HI fragment containing 5′ *Pten* genomic DNA and a 2.0 Kb *Xba*I fragment containing 3′ genomic DNA were cloned into pPNT. The targeting construct was linearized with *Not*I and electroporated into CJ7 ES cells. Transfectants were selected in G418 (350 μg/ml) and gancyclovir (2 μM) and expanded for Southern blot analysis using a 3′ probe. Chimeric mice were produced by microinjection of two independently generated targeted ES cell clones with normal karyotypes into E3.5 C57BL6/J blastocysts, then transferred to pseudopregnant foster mothers. Chimeric males were mated with C57BL6/J females (Jackson Laboratory, Bar Harbor, Maine, United States), and germline transmission of the mutant allele was verified by Southern blot analysis of tail DNA from agouti coat-colored F1 offspring. Next, *Pten*^loxP-neo/+^ mice were mated with *EIIA-Cre* transgenic mice ([@pbio.0000059-Lakso1]), and tail DNA from offspring was subjected to Southern blot analysis using probe 6.1. Through these crosses, mosaic mice harboring a *Pten* wild-type allele, a *Pten* targeted allele (*Pten*^loxP-neo^), and a floxed allele (*Pten*^loxp^) in their germline were generated. These mosaic mutants were mated with wild-type mice and tail DNA from offspring subjected to Southern blot analysis using probe 6.1 and to PCR analysis using primer 1 (5′-AAAAGTTCCCCTGCTGATGATTTGT-3′) and primer 2 (5′-TGTTTTTGACCAATTAAAGTAGGCTGTG-3′). PCR conditions were 35 cycles (30 sec at 95°C, 1 min at 55°C, and 1 min at 72°C) using HotStarTaq Master Mix (Qiagen, Valencia, California, United States), primer (0.25 μM), and DNA (50 ng). To detect the deleted allele, primer 3 (5′-CCCCCAAGTCAATTGTTAGGTCTGT-3′) was used. *Pten*^loxP/loxP^ mice were next mated with *PB-Cre* transgenic mice ([@pbio.0000059-Maddison1]) or male *PB-Cre4* transgenic mice ([@pbio.0000059-Wu1]) for conditional prostate-specific *Pten* inactivation.

### Autopsy and histopathology {#s4a3}

Animals were autopsied and all tissues were examined regardless of their pathological status. Normal and tumor tissue samples were fixed in 10% buffered formalin and embedded in paraffin. Sections (5 μm) were stained with hematoxylin and eosin (H&E) according to standard protocols.

### Cells {#s4a4}

Primary MEFs derived from ten littermate embryos were produced as follows. MEFs were obtained by crossing *Pten*^hy/+^ and *Pten*^+/−^ animals, embryos were harvested at 13.5 dpc, and individual MEFs were produced and cultured as previously described ([@pbio.0000059-Di5]) and genotyped as described above. At passage 2, cells were harvested for WB analysis (see below) and mRNA extraction by the TRIZOL method (GIBCO--BRL, Carlsbad, California, United States) and cDNA produced using the SuperScript First-Strand Kit for RT--PCR (Invitrogen, Carlsbad, California, United States) according to the manufacturers\' instructions. Semiquantitative PCR (yielding a 102 bp amplicon) was performed with a *Pten* exon 3-specific forward (5′-TGGATTCAAAGCATAAAAACCATTAC-3′) and an exon 4- and exon 5-specific reverse primer (5′-CAAAAGGATACTGTGCAACTCTGC-3′) using 30 cycles of 1 min at 95°C, 1 min at 55°C, and 1 min at 72°C) with the PCR optimizer kit (Invitrogen) and buffer A according to the manufacturer\'s protocols. PCR amplification of the cDNAs was performed for 25, 30, and 35 cycles, and the amplified products were found to be in the linear range at 30 cycles. PCR products from hypoxanthine phosphoribosyltransferase (*HPRT*) control amplification with 5′-CCTGCTGGATTACATTAAAGCACTG-3′ and 5′-GTCAAGGGCATATCCAACAACAAAC-3′ primers were used as standards (352 bp amplicon). For measuring proliferative rates of all MEF genotypes, cells were seeded in 12-well plates at 3,000 cells per well in medium containing 10% FBS and fixed at 2-d intervals. Analysis and quantification were performed as previously described ([@pbio.0000059-Di5]).

### WB analysis and densitometry {#s4a5}

Prostates from dissected animals of all genotypes were briefly homogenized (using a Polytron homogenizer; Polytron Vertrieb, Bad Wildbad, Germany), and primary MEFs were harvested and directly lysed in 50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, 1 mM sodium ortho-vanadate (Na~3~VO~4~), 10 mM NaF, and protease inhibitor cocktail (Hoffmann--La Roche, Basel, Switzerland) and cleared by centrifugation; concentrations were determined by the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, California, United States); and samples were taken into an SDS sample loading buffer.Blood was taken from the retro-orbital cavity of anesthetized mice, red cells were lysed in lysis buffer (0.155 M NH~4~Cl, 10 mM KHCO~3~, 1 mM EDTA), and intact cells harvested by centrifugation. PBMCs were lysed in lysis buffer as previously described ([@pbio.0000059-Di5]), and protein concentrations were determined as above. Equivalents of 50 μg of lysate per lane were used for SDS--PAGE and WB analysis. Proteins were detected using a rabbit polyclonal anti-Pten antibody (anti-PTEN/MMAC-1 Ab-2; NeoMarkers, Lab Vision Corporation, Fremont, California, United States), anti-actin monoclonal antibody (mAb) AC-74 (Sigma, St. Louis, Missouri, United States) for normalization, and the Phospho-Akt Pathway Sampler Kit antibodies against Akt and phospho-Serine 473 of Akt (Cell Signaling Technology, Beverly, Massachusetts, United States) following the manufacturers\' instructions. After visualization with the ECL system (Amersham Biosciences, Little Chalfont, United Kingdom), films were scanned and band density was quantified using MacBas v2.5 (Fuji Photo Film Company, Tokyo, Japan) on a Macintosh computer (Apple Computer, Sunnyvale, California, United States).

### IHC {#s4a6}

Tissues were fixed in 4% paraformaldehyde and embedded in paraffin, and 8 μm-thick sections were prepared. Anti-p27 mouse mAb (catalog \#610242; BD Transduction Laboratories, San Diego, California, United States) was used at 0.5 μg/ml concentration. The IHC detection was performed with the MOM kit from Vector Laboratories (Burlingame, California, United States). Rabbit polyclonal phospho-Akt (Ser 473) antibody (catalog \#9270 from Cell Signaling Technology) was used in 1:50 dilution, and rabbit polyclonal antibody PTEN/MMAC1 Ab-2 (catalog \#RB-072-PO from NeoMarkers) was used at 1:200 dilution. The IHC detection was performed with the ABC kit from Vector Laboratories. These staining procedures were carried out by the automated staining processor Discovery from Ventana Medical Systems (Tucson, Arizona, United States).

Anti-Ki-67 antibody (Novocastra Laboratories Ltd., Newcastle-upon-Tyne, United Kingdom), anti-Cre antibody (Novagen, Madison, Wisconsin, United States), and polyclonal anti-phospho-mTOR antibody (Cell Signaling Technology) were purchased. Anti-phospho-FOXO3 (Thr 32) was a kind gift from Anne Brunet (Harvard University, Cambridge, Massachusetts, United States). Paraffin sections (5 μm thickness) were fixed in ice-cold acetone and incubated in 0.1% H~2~O~2~ for 15 min to inactivate internal peroxidase. Antigen retrieval was performed in 10 mM citric acid for 15 min using microwave. IHC staining was performed using biotinylated secondary antibodies followed by the Vectastain ABC Elite kit (Vector Laboratories).

### MRI analysis {#s4a7}

Mice were assessed individually by MRI for tumor establishment. Images were obtained on a 1.5T General Electric LX Echo Speed Signa scanner (General Electric Medical Systems, Milwaukee, Wisconsin, United States) using homemade foil solenoid coils (22 mm or 27 mm inner diameter). The mice were anesthetized with isofluorane. Images were acquired using a two-dimensional spin-echo pulse sequence. Initially, the animal was positioned in the coil in a holder, and sagittal scout (field of view, 120 mm) images obtained (TR = 300 ms, TE = 14 ms, one excitation per phase-encoding step, 256 × 128 matrix, 3.0 mm-thick slice, 1.5 mm slice separation) to localize the region of interest. Subsequently, high-quality T~2~-weighted fast spin-echo transverse images were obtained (TR = 3,000--5,000 ms, TE~eff~ = 102 ms, echo train length = 12, 6--12 excitations per phase-encoding step, 1.5 mm thick slice, field of view = 40 mm, 0.5 mm slice separation, in plane resolution of 156 ×156 μm or 156 × 208 μm).

### Statistical analysis {#s4a8}

Survival was calculated using the Kaplan--Meier method. Log rank tests were used to compare groups by using the SPSS 10 software package (SPSS Incorporated, Chicago, Illinois, United States).
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